KPV is not approved by the U.S. FDA for human use and is not lawful to administer to humans. Where it is offered for sale in the U.S., it is sold only as a 'Research Use Only' laboratory chemical, not as a medicine.
Status as of July 14, 2026
The honest starting point is that KPV has no established, evidence-based human dose; every dosing figure in the record comes from preclinical work rather than controlled human trials. KPV is a lysine-proline-valine tripeptide from the C-terminal region of alpha-melanocyte-stimulating hormone, and the literature expresses its "dose" as laboratory concentrations and per-animal amounts, not a regimen for people.
No regulatory body has defined a therapeutic KPV dose, and the published record describes experimental exposures in cells and animals rather than a dosing regimen for humans.
The preclinical record rests on two layers of model, and the choice of both traces back to where KPV's transporter is most active. In vitro cell work measures the peptide's effect on inflammatory signaling directly, while rodent colitis models test whether that activity holds up in a living gut.
KPV's preclinical evidence comes from in vitro intestinal and immune cell lines plus chemically induced mouse colitis models, both of which demonstrate biological activity rather than clinical efficacy or a human dose.
Route is a central variable because a bare tripeptide is vulnerable to peptidase breakdown, so how KPV reaches its target changes what dose is even meaningful. A number that looks effective when the peptide is shielded inside a nanoparticle cannot be compared one-to-one with the same amount of free peptide.
| Route | Delivery form | Degradation exposure |
|---|---|---|
| Oral / drinking water | Free peptide dosed to the gut | High; faces stomach acid and peptidases |
| Nanoparticle / hydrogel | Encapsulated, targeted to inflamed sites | Low; more survives, active at lower totals |
| Enema | Local delivery to the colon | Bypasses upper-GI degradation |
Encapsulated KPV formulations often show activity at far lower total peptide amounts than free peptide, because protection from enzymatic degradation lets more of the administered dose survive to act.
In cell-based work KPV activity is described as a concentration, not a dose, and the striking pattern is that anti-inflammatory effects appear at low levels, reaching into the nanomolar-to-micromolar range in some colitis-relevant systems. An in vitro concentration is the amount of peptide bathing cells in a dish under idealized conditions, with no digestion, circulation, or clearance, so it marks potency against a target without indicating how much a person would need.
KPV suppresses inflammatory markers in the nanomolar-to-micromolar range in vitro, a measure of potency against a target that carries no direct translation to a human oral or injected dose without pharmacokinetic data that remains unsettled.
PepT1 is the mechanistic reason KPV behaves the way it does at low concentrations. Its normal job is carrying di- and tripeptide fragments from digested protein across the intestinal membrane, and because KPV is itself a tripeptide, it rides that same pathway into epithelial and immune cells.
Because KPV is a PepT1 substrate and PepT1 is upregulated in inflamed intestinal tissue, low extracellular concentrations are actively accumulated where they are needed, a saturable pathway that explains the observed potency without yielding a dose formula.
Body-weight and body-surface-area conversions are rough allometric shortcuts that assume a drug is absorbed, distributed, broken down, and cleared similarly across species. A tripeptide violates several of those assumptions at once, so extrapolating a precise human figure from rodent data would be a guess dressed up as a calculation.
Animal studies establish biological plausibility and relative potency for KPV, not a human dose, because rapid peptidase degradation, route dependence, and the absence of human pharmacokinetic data break the allometric assumptions cross-species scaling relies on.
Frequency and duration in KPV animal work track the arc of the disease model, not any clock from human practice. Because a bare tripeptide is cleared and degraded quickly, a single exposure would be too transient to sustain an effect, so daily or near-daily redosing across the inflammatory window is the norm.
KPV is typically administered on a daily or near-daily schedule across a mouse colitis model's days-long inflammatory course, a timing calibrated to the experiment rather than to any established human treatment need.
There is a real gap between the numbers in the research literature and the dosing figures circulating in the consumer research-chemical market. One is provisional laboratory data tied to a specific model, route, and formulation; the other is informal convention that grew out of community practice and product packaging.
| Criterion | Research literature | Consumer-market figures |
|---|---|---|
| Source | Controlled cell and rodent measurement | Community practice and packaging |
| Attachment | Bound to a model, route, and formulation | Stated as a fixed quantity and schedule |
| Backing | Concentration-response data | No pharmacokinetic or dose-finding study |
| Standing | Provisional laboratory data | Anecdote repeated widely |
Because the preclinical work never established a human dose, a marketed KPV figure describes what some sellers and users have settled on rather than what research has shown to be safe or effective, and the two are not genuinely comparable.
The regulatory situation is the backstop reason no standardized KPV dose exists. KPV is not an approved drug in any major jurisdiction, so no authority has run it through the phased trial program, including dedicated dose-finding studies, that turns a defined dose into an official one.
KPV is not an approved drug in any major jurisdiction, so no approved human dose has been established and none should be inferred or presented as standard.
Educational use only. This article describes what the published scientific and clinical literature reports about KPV. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
